US2021231675A1PendingUtilityA1
Methods of glycoprotein analysis
Assignee: MOMENTA PHARMACEUTICALS INCPriority: May 6, 2015Filed: Aug 31, 2020Published: Jul 29, 2021
Est. expiryMay 6, 2035(~8.8 yrs left)· nominal 20-yr term from priority
C07K 16/00C07K 2317/524G01N 2560/00H01J 49/004C07K 2319/30G01N 30/88C07K 2317/526G01N 2030/8831C07K 2317/41C07K 2317/40C07K 2317/10C07K 2317/52G01N 33/6848G01N 30/7233
60
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Characterization and production of protein preparations, e.g., therapeutic glycoprotein preparations, are described.
Claims
exact text as granted — not AI-modified1 .- 22 . (canceled)
23 . A method of characterizing higher order structure of a protein, comprising:
obtaining a first sample comprising a labeled protein in a first state, wherein the first state comprises a first level of label; exposing a second sample of the protein to a stressor to obtain a labeled protein in a second state, wherein the stressor comprises a second level of label, wherein the second level of label alters a higher-order structure of the protein; using mass spectrometry (MS) to obtain a first MS signal of the labeled protein in the first state and a second MS signal the labeled protein in the second state; and comparing the first MS signal with the second MS signal to characterize a change in the higher order structure of the protein by the stressor.
24 . The method of claim 23 , wherein using mass spectrometry comprises digesting the labeled protein to produce a plurality of labeled peptides.
25 . The method of claim 23 , wherein the first MS signal and the second MS signal each comprise a plurality of signals from an MS spectrum of the protein.
26 . The method of claim 23 , wherein the label is an isobaric label.
27 . The method of claim 26 , wherein the isobaric label comprises a TMT label, iTRAQ label, or ICAT label.
28 . The method of claim 26 , wherein the isobaric label is a TMT label.
29 . The method of claim 23 , wherein the first state is a native state and the second state is a non-native state.
30 . The method of claim 23 , wherein the protein is glycosylated.
31 . The method of claim 23 , wherein the protein is an Fc fusion protein or an antibody.
32 . The method of claim 23 , wherein the second level of label is higher than the first level of label.
33 . The method of claim 26 , wherein the label of the first sample of the protein and the label of the second sample of the protein have the same chemical structure but different mass.
34 . The method of claim 23 , further comprising:
exposing a third sample of the protein to a third level of label that alters a higher-order structure of the protein to obtain a labeled protein in a third state, using mass spectrometry to obtain a third MS signal of the labeled protein in the third state; and comparing the third MS signal with the second MS signal to characterize a change in the higher order structure of the protein.
35 . The method of claim 34 , wherein using mass spectrometry comprises digesting the labeled protein to produce a plurality of labeled peptides.
36 . The method of claim 35 , wherein the label is an isobaric label.
37 . The method of claim 36 , wherein the isobaric label comprises a TMT label, iTRAQ label, or ICAT label.
38 . The method of claim 36 , wherein the third level of label is higher than the second level of label.
39 . The method of claim 38 , wherein the label of the second sample of the protein and the label of the third sample of the protein have the same chemical structure but different mass.
40 . The method of claim 38 , wherein the protein is an Fc fusion protein or an antibody.
41 . The method of claim 40 , wherein the protein is glycosylated.Join the waitlist — get patent alerts
Track US2021231675A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.